K
Kristine E. Lynch
Researcher at University of Utah
Publications - 88
Citations - 1483
Kristine E. Lynch is an academic researcher from University of Utah. The author has contributed to research in topics: Medicine & Cohort study. The author has an hindex of 15, co-authored 65 publications receiving 762 citations. Previous affiliations of Kristine E. Lynch include United States Department of Veterans Affairs & Veterans Health Administration.
Papers
More filters
Posted ContentDOI
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Jennifer C E Lane,J Weaves,Kristin Kostka,T Duarte-Salles,Abrahao,Heba Alghoul,Osaid Alser,Thamir M. Alshammari,Patricia Biedermann,Edward Burn,Paula Casajust,Mitchell M. Conover,Aedín C. Culhane,A Daydov,Scott L. DuVall,Dmitry Dymshyts,Sergio Fernandez-Bertolin,Kristina Fišter,Jill Hardin,Laura Hester,George Hripcsak,Seamus Kent,Sajan Khosla,Spyros Kolovos,Christophe G. Lambert,J van der Lei,A Londhe,Kristine E. Lynch,Rupa Makadia,Andrea V. Margulis,Michael E. Matheny,Paras P. Mehta,Daniel R. Morales,H Morgan-Stewart,M Mossveld,Danielle Newby,Fredrik Nyberg,Anna Ostropolets,Rae Woong Park,A Prats Uribe,R Gowtham,Christian G. Reich,Jenna Reps,Peter R. Rijnbeek,Sathappan Smk.,Martijn J. Schuemie,Sarah Seager,Anthony G. Sena,Azza Shoaibi,Matthew E. Spotnitz,Marc A. Suchard,Joel N. Swerdel,C Torre,David Vizcaya,Haini Wen,M. de Wilde,Seng Chan You,Lin Zhang,Oleg Zhuk,Patrick B. Ryan,D Prieto Alhambra +60 more
TL;DR: Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length.
Journal ArticleDOI
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.
Jennifer C E Lane,James Weaver,Kristin Kostka,Talita Duarte-Salles,Maria Tereza Fernandes Abrahão,Heba Alghoul,Osaid Alser,Thamir M. Alshammari,Patricia Biedermann,Juan M. Banda,Edward Burn,Paula Casajust,Mitchell M. Conover,Aedín C. Culhane,Alexander Davydov,Scott L. DuVall,Scott L. DuVall,Dmitry Dymshyts,Sergio Fernandez-Bertolin,Kristina Fišter,Jill Hardin,Laura Hester,George Hripcsak,George Hripcsak,Benjamin Skov Kaas-Hansen,Seamus Kent,Sajan Khosla,Spyros Kolovos,Christophe G. Lambert,Johan van der Lei,Kristine E. Lynch,Kristine E. Lynch,Rupa Makadia,Andrea V. Margulis,Michael E. Matheny,Paras P. Mehta,Daniel R. Morales,H Morgan-Stewart,Mees Mosseveld,Danielle Newby,Fredrik Nyberg,Anna Ostropolets,Rae Woong Park,Albert Prats-Uribe,Gowtham A. Rao,Christian G. Reich,Jenna Reps,Peter R. Rijnbeek,Selva Muthu Kumaran Sathappan,Martijn J. Schuemie,Sarah Seager,Anthony G. Sena,Anthony G. Sena,Azza Shoaibi,Matthew E. Spotnitz,Marc A. Suchard,Carmine O. Torre,David Vizcaya,Haini Wen,Marcel de Wilde,Junqing Xie,Seng Chan You,Lin Zhang,Lin Zhang,Oleg Zhuk,Patrick B. Ryan,Patrick B. Ryan,Daniel Prieto-Alhambra +67 more
TL;DR: Hydxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality.
Journal ArticleDOI
Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.
Daniel R. Morales,Mitchell M. Conover,Seng Chan You,Nicole L. Pratt,Kristin Kostka,Talita Duarte-Salles,Sergio Fernandez-Bertolin,María Aragón,Scott L. DuVall,Scott L. DuVall,Kristine E. Lynch,Kristine E. Lynch,Thomas Falconer,Kees van Bochove,Cynthia Sung,Michael E. Matheny,Christophe G. Lambert,Fredrik Nyberg,Thamir M. Alshammari,Andrew E. Williams,Rae Woong Park,James Weaver,Anthony G. Sena,Anthony G. Sena,Martijn J. Schuemie,Peter R. Rijnbeek,Ross D. Williams,Jennifer C E Lane,Albert Prats-Uribe,Lin Zhang,Lin Zhang,Carlos Areia,Harlan M. Krumholz,Daniel Prieto-Alhambra,Patrick B. Ryan,Patrick B. Ryan,George Hripcsak,Marc A. Suchard +37 more
TL;DR: No clinically significant increased risk of COVID-19 diagnosis or hospital admission-related outcomes associated with ACEI or ARB use was observed, suggesting users should not discontinue or change their treatment to decrease their risk ofCO VID-19.
Journal ArticleDOI
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.
Liam Gaziano,Claudia Giambartolomei,Alexandre C. Pereira,Anna Gaulton,Daniel C Posner,Sonja A. Swanson,Yuk-Lam Ho,Sudha K Iyengar,Nicole M Kosik,Marijana Vujkovic,David R. Gagnon,David R. Gagnon,A. Patrícia Bento,Inigo Barrio-Hernandez,Lars Rönnblom,Niklas Hagberg,Christian Lundtoft,Claudia Langenberg,Maik Pietzner,Dennis Valentine,Stefano Gustincich,Gian Gaetano Tartaglia,Elias Allara,Praveen Surendran,Stephen Burgess,Jing Hua Zhao,James E. Peters,Bram P. Prins,Emanuele Di Angelantonio,Poornima Devineni,Yunling Shi,Kristine E. Lynch,Scott L. DuVall,Helene Garcon,Lauren O Thomann,Jin Zhou,Bryan R Gorman,Jennifer E. Huffman,Christopher J. O'Donnell,Philip S. Tsao,Jean C. Beckham,Saiju Pyarajan,Sumitra Muralidhar,Grant D. Huang,Rachel Ramoni,Pedro Beltrao,John Danesh,Adriana M. Hung,Kyong-Mi Chang,Yan V. Sun,Jacob Joseph,Jacob Joseph +51 more
TL;DR: In this paper, Mendelian randomization analyses were conducted to identify therapeutic targets relevant to COVID-19, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development.
Journal ArticleDOI
Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study
Edward Burn,Seng Chan You,Anthony G. Sena,Anthony G. Sena,Kristin Kostka,Hamed Abedtash,Maria Tereza Fernandes Abrahão,Amanda Alberga,Heba Alghoul,Osaid Alser,Thamir M. Alshammari,María Aragón,Carlos Areia,Juan M. Banda,Jaehyeong Cho,Aedín C. Culhane,Alexander Davydov,Frank J. DeFalco,Talita Duarte-Salles,Scott L. DuVall,Scott L. DuVall,Thomas Falconer,Sergio Fernandez-Bertolin,Weihua Gao,Asieh Golozar,Jill Hardin,George Hripcsak,George Hripcsak,Vojtech Huser,Hokyun Jeon,Yonghua Jing,Chi Young Jung,Benjamin Skov Kaas-Hansen,Denys Kaduk,Seamus Kent,Yeesuk Kim,Spyros Kolovos,Jennifer C E Lane,Hyejin Lee,Kristine E. Lynch,Kristine E. Lynch,Rupa Makadia,Michael E. Matheny,Paras P. Mehta,Daniel R. Morales,Karthik Natarajan,Karthik Natarajan,Fredrik Nyberg,Anna Ostropolets,Rae Woong Park,Jimyung Park,Jose D. Posada,Albert Prats-Uribe,Gowtham A. Rao,Christian G. Reich,Yeunsook Rho,Peter R. Rijnbeek,Lisa M. Schilling,Martijn J. Schuemie,Nigam H. Shah,Azza Shoaibi,Seok Young Song,Matthew E. Spotnitz,Marc A. Suchard,Joel N. Swerdel,David Vizcaya,Salvatore Volpe,Haini Wen,Andrew E. Williams,Belay Birlie Yimer,Lin Zhang,Lin Zhang,Oleg Zhuk,Daniel Prieto-Alhambra,Patrick B. Ryan,Patrick B. Ryan +75 more
TL;DR: Protecting groups vulnerable to influenza is likely a useful starting point in the response to COVID-19, strategies will likely need to be broadened to reflect the particular characteristics of individuals being hospitalised with CO VID-19.